Search clinical trials for: P1101 + Ribavirin

Total 1664 results

Hoffmann-La Roche

Completed

POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).

Hepatitis C, Chronic

Brazil
Transgene

Completed

Efficacy of the Therapeutic Vaccine TG4040 Combined With Pegylated Interferon and Ribavirin in Chronic HCV Patients (HCVac)

Chronic Hepatitis C Infection

Germany
Teva Pharmaceuticals USA

Completed

Ribavirin 200 mg Tablets Under Non-Fasting Conditions

Healthy

United States
Vertex Pharmaceuticals Incorporated

Completed

Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

Hepatitis C

United States, Puerto Rico
Hepatitis Resource Network
Integrated Therapeutics Group; Subsidiary of Schering-Plough

Completed

PEG-Interferon a-2b + Ribavirin for Treatment of Chronic HRN 005 Hepatitis C Infection in HIV-Infected Persons Not Previously Treated With Interferon

HIV Infections | Chronic Hepatitis C Infection in HIV-Infected Persons

United States
Hopital A Michallon
Central Hospital, Nancy, France; University Hospital, Grenoble

Terminated

Plasma Ribavirin Assay During Combination Therapy for Chronic Hepatitis C

Chronic Hepatitis C

France
Janssen Research & Development, LLC

Completed

Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy

Multiple Myeloma

China
Hoffmann-La Roche

Completed

A Study of Ribavirin in Combination With PEGASYS (Peginterferon Alfa-2a (40KD))in Patients With Chronic Hepatitis C

Hepatitis C, Chronic

Russian Federation
Ortho Biotech Products, L.P.

Completed

A Study to Evaluate the Erythropoietic Response in Hepatitis C Virus (HCV) Patients Receiving Combination Ribavirin (RBV)/Interferon (IFN) Therapy or RBV/PEG IFN (NATURAL HISTORY-HCV)

Anemia | Hepatitis C
Azienda Ospedaliera di Padova
University of Padova; Regione Veneto

Completed

Different PEG-interferon and Ribavirin Schedules for Chronic Hepatitis C in the Real Clinical Practice.

Hepatitis C Virus | Chronic Liver Disease | Therapeutic Uses | Viral Hepatitis | Antiviral Agents

Italy
National Taiwan University Hospital
Hoffmann-La Roche

Unknown

Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C/Hepatitis B Co-Infection and Chronic Hepatitis C

Hepatitis C, Chronic | Hepatitis B, Chronic

Taiwan
Hoffmann-La Roche

Completed

A Study of Sustained Virological Response in Relation to IL28-b Expression in Treatment-Naïve Patients With Chronic Hepatitis C Genotype 1 on Combination Treatment With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

Hepatitis C, Chronic

Brazil
Hoffmann-La Roche

Withdrawn

A Study of the Safety of Individualized Combination Therapy With Copegus (Ribavirin) and Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis C (MASTER)

Hepatitis C, Chronic
Azienda Ospedaliero-Universitaria di Parma

Completed

Effect of Boceprevir on HCV-specific T Cell Responses (Boce-Par)

Chronic Hepatitis C

Italy
Casa Sollievo della Sofferenza IRCCS
University of Palermo; University of Florence; Campus Bio-Medico University; IRCCS... and other collaborators

Completed

Different Ribavirin Dosages and Different Duration of Treatment in Combination With PegInterferon in Patients With Genotype 2 and 3 (WRITE) (WRITE)

Chronic Hepatitis

Italy
GlobeImmune

Completed

Safety and Efficacy of the Therapeutic Vaccine GI-5005 Combined With Pegylated Interferon Plus Ribavirin Standard of Care Therapy Versus Standard of Care Alone in Patients With Genotype 1 Chronic Hepatitis C Infection

Genotype 1 Chronic Hepatitis C

United States
Karolinska Institutet
The Swedish Research Council; Hoffmann-La Roche

Completed

Interactions of Hepatitis C Viral (HCV) Dynamics and Immune Activation in HIV Coinfected Patients During HCV Treatment (DICO)

Chronic Hepatitis C | Human Immunodeficiency Virus

Sweden
Vertex Pharmaceuticals Incorporated

Terminated

A Safety and Efficacy Study of the Combination of VX-222 and Telaprevir in Treatment-Naïve Subjects With Genotype 1 Chronic Hepatitis C Virus Infection

Chronic Hepatitis C Virus Infection

United States, New Zealand
Egyptian Liver Hospital
Wadi El Nil Hospital

Completed

A Study to Evaluate the Safety and Efficacy of the Combined Single Dose of Dactavira Plus Or Dactavira in Egyptian Adults With Chronic Genotype 4 HCV Infection

Hepatitis C

Egypt
Hoffmann-La Roche

Completed

A Study of RO5024048 in Combination With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin) in Patients With Chronic Hepatitis C Genotype 1 or 4

Hepatitis C, Chronic

United States, Canada
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Pioglitazone Before Peginterferon and Ribavirin for Hepatitis C Infection in HIV/HCV-Coinfected Patients With Insulin Resistance

HIV-1 and Hepatitis C Co-Infection

United States
Sandoz

Completed

Relative Bioavailability Study of Ribavirin 200 Capsules and Rebetol 200 mg Capsules in Females Under Non-Fasting Conditions

Chronic Hepatitis C
Pacific Health Foundation
Hoffmann-La Roche

Completed

Pegasys and Copegus for Asian Patients With Treatment-naive Hepatitis C Genotypes 6, 7, 8, 9

Chronic Hepatitis C | Treatment | Asian Americans | Novel Genotypes

United States
UPECLIN HC FM Botucatu Unesp

Completed

Factors Associated to Success of Hepatitis C Therapy

Hepatitis, Viral, Non-A, Non-B, Parenterally-Transmitted

Brazil
Boehringer Ingelheim

Withdrawn

Open Label Trial to Compare BI 207127 to Telaprevir in HCV Patients

Hepatitis C, Chronic

Australia, Spain, Sweden
National Taiwan University Hospital
National Science Council, Taiwan; National Health Research Institutes, Taiwan

Unknown

Pegylated Interferon Alfa-2b Plus Ribavirin in Chronic Hepatitis B and Delta

Chronic Hepatitis B | Chronic Hepatitis D

Taiwan
Germans Trias i Pujol Hospital
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la...

Completed

Viral Kinetics of Treatment With Peginterferon Alpha-2a, Ribavirin and Epoetin β in Patients Coinfected HCV/HIV

HIV Infections

Spain
Merck Sharp & Dohme LLC

Completed

Vaniprevir Plus PegIntron®/Ribavirin in Japanese Participants With Chronic Hepatitis C Who Are Non-responders to Previous Treatment (MK-7009-045)

Hepatitis C, Chronic
Kadmon Corporation, LLC

Terminated

Infergen and Ribavirin Treatment of Patients With HCV Who Achieved Partial Response to Peginterferon-alfa and Ribavirin (ENHANCE)

Hepatitis C

United States
NORDynamIC Study Group

Completed

Multicenter Study Evaluating 12 Versus 24 Weeks Therapy With Peginterferon and Ribavirin for Hepatitis C Virus (HCV) Genotype 2 or 3

Hepatitis C Virus

Sweden
Patara Pharma

Completed

Treatment of Refractory Chronic Cough With PA101

Refractory Chronic Cough

Netherlands, United Kingdom
Ain Shams University

Completed

Sofosbuvir and Simeprevir Versus Sofosbuvir and Ribavirin in Treatment of HCV

HCV
Dongguan HEC TaiGen Biopharmaceuticals Co., Ltd.
Peking University People's Hospital

Completed

To Evaluate Efficacy and Safety in TG-2349 Combination With DAG181 (± Ribavirin) in HCV Genotype I Infected Patients

Cirrhosis | Chronic Hepatics C Virus (HCV) Genotype 1 | Non-Cirrhotic | Treatment naïve

China
amfAR, The Foundation for AIDS Research
Kirby Institute

Completed

HCV Treatment in HIV Co-Infected Patients in Asia

Hepatitis C | HIV

Vietnam, Malaysia, Indonesia, Thailand
Merck Sharp & Dohme LLC

Completed

Boceprevir (SCH 503034) Plus Peg-Intron, With and Without Added Ribavirin, in Patients With Chronic Hepatitis C, Genotype 1, Who Did Not Respond to Previous Treatment With Peginterferon Alfa Plus Ribavirin (Study P03659AM2)(COMPLETED)

Chronic Hepatitis C
Prof. Facchinetti Fabio
Merck Sharp & Dohme LLC

Completed

Menopause is a Critical Factor in Determining Failure of Antiviral Therapy in Women With Chronic Hepatitis C (MEN_EPID)

Chronic Hepatitis C

Italy
Hospital Carlos III, Madrid

Completed

Pilot Study of Patients Chronic Hepatitis C in Co-infected HIV Patients Relapsers After Previous Therapies (PILOT-NR)

HIV Infections | Chronic Hepatitis C

Spain
Mansoura University

Recruiting

MANS-NRIZ Trial for COVID-19 Treatment : Extension Study

COVID-19 Pneumonia

Egypt
Institut de Recherche pour le Developpement
Ministry of Health, Thailand

Completed

HCV-HIV Co-infected Patient Cohort in Thailand

HIV | Hepatitis C Infection

Thailand
Dynavax Technologies Corporation
PPD; Synteract, Inc.

Completed

Safety Study of SD-101 (a Novel C Type Toll-like Receptor 9 (TLR9) Agonist) for the Treatment of Chronic Hepatitis C Virus (HCV) Infection

Chronic Hepatitis C

Poland
Merck Sharp & Dohme LLC

Completed

Safety and Efficacy of PegIntron and Rebetol Combination Therapy in Patients With Chronic Hepatitis C in Japan (Study P04505)

Hepatitis C | Hepatitis C, Chronic
Benha University

Completed

Effect of New Oral Treatment for Hepatitis C Virus on Seminal Parameters

Male Infertility | HCV

Egypt
Kaohsiung Medical University Chung-Ho Memorial...

Unknown

Peginterferon Plus Ribavirin for Hepatitis C Patients Concomitant With Hepatocellular Carcinoma

Hepatocellular Carcinoma | Chronic Hepatitis C

Taiwan
Centre hospitalier de l'Université de Montréal...
Hoffmann-La Roche; Centre de Recherche du Centre Hospitalier de l'Université...

Completed

Ribavirin Dose Optimization for the Treatment of Hepatitis C

Chronic Hepatitis C

Canada
Hepasome Pharmaceuticals

Unknown

HDV-Interferon in the Treatment of Chronic Hepatitis C Nonresponders and Naive Hepatitis C Patients

Chronic Hepatitis C

India
Mclean Hospital
University of California, San Francisco; Center for Medicinal Cannabis Research

Recruiting

A Clinical Trial of a Hemp-Derived, High Cannabidiol Product for Anxiety in Glioblastoma Patients

Glioblastoma

United States
Beth Israel Medical Center
InterMune

Completed

Study of High Dosage CIFN Plus RBV for HCV Genotype 1 Infected Patients Who Are Nonresponders to Prior Therapy

Hepatitis C

United States
Mansoura University

Unknown

New Antiviral Drugs for Treatment of COVID-19

COVID | Drug Effect

Egypt
Chang Gung Memorial Hospital

Terminated

Sustained Virological Response (SVR)Rate of Pegasys Plus Ribavirin in Patients With Chronic Hepatitis C

Chronic Hepatitis C

Taiwan
University of Ulm
Hoffmann-La Roche

Completed

Influence of Antiviral Therapy on Bone Mineral Density and Metabolism in Patients With Chronic Hepatitis C

Liver Diseases | Virus Diseases | Hepatitis C, Chronic

Germany

3

Subscribe